CEO Zook exits Vivus, J&J's Fischer steps in
This article was originally published in Scrip
Vivus' freshly appointed CEO, Tony Zook who joined the Mountain View, California-based firm from big pharma AstraZeneca, has stepped down due to "a previously-diagnosed medical condition." Taking up the position instead is Seth H Z Fischer, former Johnson and Johnson company group, and worldwide franchise chair – effective 3 September 2013. Mr Fischer will also join the Vivus board of directors.
You may also be interested in...
Orexigen hoped its go-it-alone strategy would boost obesity drug Contrave's sales enough to keep the company afloat, but now it has initiated bankruptcy proceedings, following through on a warning in October that it might not meet debt holders' requirements.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.